Lys255
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Acetylation Site Page: > Lys255  -  COL5A3 (human)

Site Information
GkGkGRkkGRGRKGK   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 461857

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 )
Disease tissue studied:
liver cancer ( 5 ) , hepatocellular carcinoma ( 5 )
Relevant cell line - cell type - tissue:

References 

1

Possemato A (2006) CST Curation Set: 2187; Year: 2006; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

2

Li Y (2006) CST Curation Set: 1640; Year: 2006; Biosample/Treatment: cell line, SNU-C2B/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

3

Li Y (2006) CST Curation Set: 1633; Year: 2006; Biosample/Treatment: cell line, HT-29/untreated &'||' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

4

Li Y (2006) CST Curation Set: 1567; Year: 2006; Biosample/Treatment: cell line, NCI-H716/untreated &'||' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

5

Mitchell J (2005) CST Curation Set: 867; Year: 2005; Biosample/Treatment: cell line, HepG2/TSA; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info